Royalty Pharma Announces Upcoming Investor Day
NEW YORK, NY, March 27, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET.
News
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
NEW YORK, NY, February 27, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET.
Royalty Pharma Announces R&D Funding Collaboration with Biogen
NEW YORK, NY, February 12, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
Royalty Pharma Reports Q4 and Full Year 2024 Results
NEW YORK, NY, February 11, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts.
Royalty Pharma Announces Sale of Morphosys Development Funding Bonds
NEW YORK, NY, January 29, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash.
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
NEW YORK, NY, January 28, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open.
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, NY, January 10, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts.
Royalty Pharma Announces Transformative Step in Company’s Evolution with Acquisition of its External Manager and $3 Billion Share Repurchase Program
NEW YORK, NY, January 10, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced two major steps to enhance shareholder value.
Royalty Pharma Announces Dividend Increase
NEW YORK, NY, January 9, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend.
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, NY, November 27, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December.
